Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John Bradley Schmieder Sells 2,500 Shares

Mesa Laboratories, Inc. (NASDAQ:MLABGet Rating) Director John Bradley Schmieder sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $175.45, for a total value of $438,625.00. Following the transaction, the director now directly owns 68,976 shares in the company, valued at approximately $12,101,839.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Mesa Laboratories Stock Performance

NASDAQ:MLAB opened at $184.15 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.13 and a current ratio of 2.80. Mesa Laboratories, Inc. has a fifty-two week low of $114.21 and a fifty-two week high of $333.42. The company has a market cap of $982.81 million, a price-to-earnings ratio of -242.30 and a beta of 0.60. The stock has a fifty day moving average price of $147.21 and a 200-day moving average price of $180.16.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 15th. Stockholders of record on Wednesday, November 30th will be paid a $0.16 dividend. The ex-dividend date is Tuesday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.35%. Mesa Laboratories’s payout ratio is -84.21%.

Institutional Investors Weigh In On Mesa Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in MLAB. State of New Jersey Common Pension Fund D bought a new stake in shares of Mesa Laboratories during the 2nd quarter valued at about $2,185,000. Exchange Traded Concepts LLC lifted its holdings in shares of Mesa Laboratories by 3.0% in the second quarter. Exchange Traded Concepts LLC now owns 5,074 shares of the medical instruments supplier’s stock valued at $1,035,000 after purchasing an additional 146 shares in the last quarter. Nisa Investment Advisors LLC purchased a new stake in shares of Mesa Laboratories during the second quarter valued at approximately $414,000. Envestnet Asset Management Inc. increased its position in shares of Mesa Laboratories by 13.7% during the second quarter. Envestnet Asset Management Inc. now owns 12,790 shares of the medical instruments supplier’s stock valued at $2,608,000 after acquiring an additional 1,546 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Mesa Laboratories by 9.5% during the first quarter. New York State Common Retirement Fund now owns 6,882 shares of the medical instruments supplier’s stock valued at $1,754,000 after acquiring an additional 596 shares during the last quarter. Institutional investors and hedge funds own 92.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Evercore ISI boosted their price target on Mesa Laboratories to $166.00 in a research report on Tuesday, November 15th. StockNews.com raised Mesa Laboratories from a “sell” rating to a “hold” rating in a report on Friday, November 4th.

Mesa Laboratories Company Profile

(Get Rating)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.

Recommended Stories

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.